Souhaitez-vous accéder aux communiqués récents ?

20,000 patients have been treated with JETREA® globally since its launch Leuven, November 13, 2015 - ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on...

ThromboGenics Announces FDA Acceptance of Investigational New Drug (IND) Application for Phase II Study with JETREA® for the Treatment of Non-Proliferative Diabetic Retinopathy (CIRCLE) ...

Regulated information ThromboGenics Business Update - Q3 2015          US organization adapted for break-even from 2016 onwards Since launch, 20,000 patients treated globally with JETREA® ...

Regulated Information - Transparency Statement Leuven, Belgium, 10 September 2015 - Pursuant to Belgian transparency legislation (Law of 2 May 2007), ThromboGenics NV (Euronext Brussels: THR)...

Regulated information                                      US organisation right-sized to meet current market needstargeting break-even in US from 2016 ThromboGenics clinical and pre-clinical...

Leuven, June 26, 2015 - Oncurious NV, an oncology company focused on the development of innovative medicines for the treatment of pediatric tumors, today announces the appointment of Prof Dr Peter...

REGULATED INFORMATION New clinical studies for JETREA® confirm positive OASIS results: 28 days post injection resolution rates ranging from around 40% to 58% New JETREA® ready-diluted formulation...

Company receives € 0.6 million research grant from IWT, the Flemish Agency for Innovation by Science and Technology    Leuven, April 23, 2015 - ThromboGenics NV (Euronext Brussels: THR), an...

    Oncurious NV to develop TB-403 for Pediatric Brain Tumors  Leuven, April 14, 2015 - ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and...

ThromboGenics Announces Positive Topline Results from OASIS Study   OASIS Study Meets Primary Endpoint with 41.7% of Patients Treated with JETREA® achieving VMA resolution at Day 28 post injection...